Graves’ disease is an autoimmune disease of the thyroid gland, in which the thyroid attacked by the body’s own defence mechanisms becomes enlarged and produces increased amount of hormones, causing hyperthyroidism. The condition induces signs and symptoms that seriously affect the patient’s quality of life, everyday activities and ability to work.
This report provides the current prevalent population for Graves’ disease across 23 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, The Netherlands, Norway, Sweden, Austria, Denmark, Iceland, Switzerland, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Graves’ disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
The quantified symptoms and co-morbidities for Graves’ disease include:
- Graves' Ophthalmopathy
- Thyroid dermopathy
Moreover, forecasts of some clinical and family history parameters are provided at a country level.
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
- Able to quantify patient populations in global Graves’ disease’s market to target the development of future products, pricing strategies and launch plans.
- Gain further insight into the prevalence of the subdivided types of Graves’ disease and identify patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Provide a level of understanding on the impact from specific co-morbid conditions on Graves’ disease’s prevalent population.
- Identify sub-populations within Graves’ disease which require treatment.
- Gain an understanding of the specific markets that have the largest number of Graves’ disease patients.